Highlights
- Low-dose gemcitabine/cisplatin (LDGC) combined with anti-PD-L1 significantly improves the tumor immune microenvironment (TIME) compared to standard-dose regimens.
- The mechanism involves the reduction of immunosuppressive SPP1+ tumor-associated macrophages (TAMs) and the promotion of CD8+ T cell infiltration.
- LDGC reprograms the STAT1 and STAT3 transcriptional pathways in macrophages, downregulating the SPP1-VLA-4 inhibitory axis.
- Pilot clinical data demonstrate superior patient tolerance and enhanced antitumor responses in intrahepatic cholangiocarcinoma (ICC).
Background
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with a rising global incidence and a historically poor prognosis. For patients with advanced disease, the combination of gemcitabine and cisplatin (GC) has long been the backbone of systemic therapy. The integration of immune checkpoint inhibitors (ICIs), specifically anti-PD-L1 (e.g., durvalumab as seen in the TOPAZ-1 trial), has recently established a new first-line standard of care. However, despite this progress, the objective response rates remain modest, and the therapeutic ceiling is often reached due to profound immunosuppression within the hepatic microenvironment and the cumulative toxicity of full-dose chemotherapy.
The tumor immune microenvironment (TIME) in ICC is characterized by a dense stroma and a high prevalence of immunosuppressive cells, particularly tumor-associated macrophages (TAMs). These cells often orchestrate T-cell exclusion and exhaustion, rendering ICIs less effective. Emerging evidence suggests that chemotherapy, when administered at lower doses, may act more as an immunomodulator than a purely cytotoxic agent. This study by Zhixing L. et al. (Hepatology, 2026) investigates whether a low-dose gemcitabine/cisplatin (LDGC) approach can effectively remodel this landscape to sensitize ICC to PD-L1 blockade.
Key Content
The Rationale for Low-Dose Chemotherapy in ICC
Conventional chemotherapy aims for the maximum tolerated dose (MTD) to achieve direct tumor lysis. However, MTD often results in systemic lymphopenia and damage to the very immune populations required for a successful response to immunotherapy. In contrast, low-dose or metronomic chemotherapy has been shown in various solid tumors to exert pro-inflammatory effects, such as inducing immunogenic cell death (ICD) or selectively depleting myeloid-derived suppressor cells (MDSCs).
Remodeling the Hepatic Immune Landscape
Using multiple preclinical ICC mouse models, researchers demonstrated that LDGC combined with anti-PD-L1 therapy led to a marked reduction in tumor burden compared to monotherapy or standard-dose combinations. Single-cell RNA sequencing (scRNA-seq) revealed a profound shift in the cellular composition of the TIME. Specifically, the combination treatment led to a significant decrease in a specific subset of macrophages characterized by the expression of Secreted Phosphoprotein 1 (SPP1), also known as osteopontin.
These SPP1+ TAMs are increasingly recognized as major mediators of fibrosis and immune evasion in the liver. Their reduction was accompanied by a concomitant increase in the density and functional activity of CD8+ T cells. Flow cytometry confirmed that these T cells exhibited higher levels of Granzyme B and Interferon-gamma (IFN-γ), indicating restored cytotoxicity.
Molecular Mechanisms: The STAT1-STAT3-SPP1 Axis
The study provides deep mechanistic insights into how LDGC affects macrophage polarization. At the transcriptional level, LDGC was found to modulate the interplay between Signal Transducer and Activator of Transcription 1 (STAT1) and STAT3. While STAT3 typically promotes the pro-tumorigenic M2-like phenotype and SPP1 expression, STAT1 is associated with M1-like anti-tumor activity.
LDGC treatment favored STAT1 signaling over STAT3, directly leading to the downregulation of SPP1. This is critical because SPP1 interacts with Very Late Antigen-4 (VLA-4) on the surface of CD8+ T cells. This SPP1-VLA-4 signaling axis acts as a molecular brake on T cells, inhibiting their migration and killing capacity. By neutralizing this axis, LDGC essentially “unleashes” the T cells to respond to the PD-L1 blockade.
Translational and Clinical Evidence
The findings were validated using patient-derived tumor fragments, which maintained the architectural and cellular complexity of human ICC. Furthermore, a pilot clinical trial involving ICC patients was conducted to assess the feasibility of this low-dose approach. Preliminary results indicated that patients receiving the LDGC plus anti-PD-L1 regimen achieved superior clinical responses with a notably better safety profile—specifically fewer episodes of grade 3/4 myelosuppression—compared to historical cohorts receiving standard doses.
Expert Commentary
The transition from “more is better” to “optimal modulation” represents a significant shift in oncological thinking. The work by Zhixing L. and colleagues provides a compelling biological rationale for using low-dose chemotherapy as a surgical tool to reshape the immune microenvironment rather than a blunt instrument of destruction.
The identification of SPP1+ macrophages as the primary target of LDGC is particularly relevant. Recent pan-cancer analyses have identified SPP1+ macrophages as a key feature of tumors resistant to ICIs. In the context of the liver, where the environment is naturally immunotolerant, targeting these cells is essential. The modulation of the STAT1/STAT3 ratio provides a clear biomarker-driven pathway that could, in the future, be used to select patients most likely to benefit from this regimen.
However, several questions remain. The optimal “low dose” needs precise definition across different patient populations, and the long-term durability of the response compared to standard dosing requires larger, randomized phase III trials. Additionally, while the focus here was on GC, it is worth investigating if other cytotoxic agents could exert similar immunomodulatory effects at sub-therapeutic doses.
Conclusion
This study demonstrates that low-dose gemcitabine and cisplatin, when combined with anti-PD-L1 therapy, can effectively remodel the immunosuppressive microenvironment of intrahepatic cholangiocarcinoma. By targeting the STAT1/STAT3-SPP1-VLA-4 signaling axis, LDGC reduces the inhibitory influence of SPP1+ macrophages and potentiates CD8+ T-cell-mediated anti-tumor immunity. These findings offer a promising strategy to improve the efficacy and reduce the toxicity of first-line treatments for ICC, moving us closer to a more personalized and precision-based approach to immuno-oncology in biliary tract cancers.
References
- Zhixing L, Liu S, Yu H, et al. Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma. Hepatology (Baltimore, Md.). 2026-03-04. PMID: 41779955.
- Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8). (Contextual reference for TOPAZ-1).
- Zhang L, Li Z, Skrzypczynska KM, et al. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell. 2020;181(2):442-459. (Contextual reference for SPP1+ TAMs).
